基于血清学数据与模型预测未来基孔肯雅疫苗试验点的预期终点事件
为指导基孔肯雅疫苗 efficacy 试验的选址,研究者开发了一个新框架:先利用系统综述汇集的血清学数据估计既往暴发的时间与规模参数,再用 SIR 传播模型预测假设未来试验期间发生暴发时的感染 attack rate,进而推算该试验点可预期的终点事件数。结果提示部分地点具有足够传播潜力和易感性以支持未来疫苗试验;过去10年内发生过暴发的地点可能较不适合近期开展基孔肯雅疫苗 efficacy 试验;该框架还可按年龄预测终点事件数,有助于受试者招募。
要点
- 新框架结合血清学数据与SIR模型预测疫苗试验点预期终点事件数。
- 过去10年内发生过暴发的地点可能较不适合近期开展基孔肯雅疫苗 efficacy 试验。
- 框架可按年龄预测终点事件数,辅助受试者招募。
核心结论
- 部分地点可能具有足够传播潜力和易感性,若在当地发生暴发,可支持未来疫苗试验。
- 总体而言,过去10年内经历过暴发的地点可能较不适合近期开展基孔肯雅疫苗 efficacy 试验。
- 该框架可按年龄预测终点事件数,有助于指导受试者招募。
研究设计与样本
- 研究开发了一个新框架,用于预测特定地点可预期的终点事件数。
- 框架首先利用系统综述汇集的血清学数据纳入人群免疫,估计既往暴发的时间与规模参数。
- 随后使用SIR传播模型预测假设未来试验期间发生暴发时的感染 attack rate,并推算终点事件数。
主要发现
- 结果提示部分地点可能具有足够传播潜力和易感性,若在当地发生暴发,可支持未来疫苗试验。
- 过去10年内经历过暴发的地点可能较不适合近期开展基孔肯雅疫苗 efficacy 试验。
- 框架可生成按年龄分层的终点事件数预测。
临床怎么用
- 该框架可用于指导基孔肯雅疫苗 efficacy 试验的选址决策。
- 按年龄预测的终点事件数可用于指导受试者招募工作。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent decades, there has been an increased interest in developing a vaccine for chikungunya. However, due to its unpredictable transmission, planning for a chikungunya vaccine trial is challenging. To inform decision making on the selection of sites for a vaccine efficacy trial, we developed a new framework for projecting the expected number of endpoint events at a given site. In this framework, we first accounted for population immunity using serological data collated from a systematic review and used it to estimate parameters related to the timing and size of past outbreaks, as predicted by an SIR transmission model. Then, we used that model to project the infection attack rate of a hypothetical future outbreak, in the event that one were to occur at the time of a future trial. This informed projections of how many endpoint events could be expected if a trial were to take place at that site. Our results suggest that some sites may have sufficient transmission potential and susceptibility to support future vaccine trials, in the event that an outbreak were to occur at those sites. In general, we conclude that sites that have experienced outbreaks within the past 10 years may be poorer targets for chikungunya vaccine efficacy trials in the near future. Our framework also generates projections of the numbers of endpoint events by age, which could inform study participant recruitment efforts.
引用
- Tran QM, Soda J, Siraj A, et al. Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling. Vaccine. 2022. PMID: 36424258. doi:10.1016/j.vaccine.2022.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。